{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:14Z","timestamp":1787008514399,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["NCT03370133"],"award-info":[{"award-number":["NCT03370133"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["NCT03410992"],"award-info":[{"award-number":["NCT03410992"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["NCT03412747"],"award-info":[{"award-number":["NCT03412747"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","award":["NCT03598790"],"award-info":[{"award-number":["NCT03598790"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the chronic nature of psoriasis and the loss of response that can be observed with therapies over time, it is important to understand the long-term efficacy of new treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate maintenance of Week 16 responses with bimekizumab (BKZ) treatment through Year 3, in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were pooled from BKZ-treated patients in the 52-week (BE VIVID) and 56-week (BE READY and BE SURE) phase III studies, and their ongoing open-label extension (OLE), BE BRIGHT. Efficacy outcomes are reported through 3\u2005years of BKZ treatment in patients with an efficacy response at Week 16. Missing data were imputed primarily using modified nonresponder imputation (mNRI), with nonresponder imputation and observed case data also reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 989 patients were randomized to BKZ at baseline in BE VIVID, BE READY and BE SURE. At Week 16, 693 patients achieved \u2265 90% reduction from baseline in Psoriasis Area and Severity Index (PASI 90), 503 achieved 100% reduction from baseline in PASI (PASI 100), 694 achieved absolute PASI \u2264 2 and 597 achieved body surface area (BSA) \u2264 1%, and continued into the OLE. Of these, 93.0% maintained PASI 90, 80.8% maintained PASI 100, 94.0% maintained PASI \u2264 2 and 90.3% maintained BSA \u2264 1% responses through to 3\u2005years of BKZ treatment (mNRI). Among Week 16 PASI 90 responders, 96.8% and 72.5% also achieved Investigator\u2019s Global Assessment 0\/1 and PASI 100 at Week 16, respectively, and 92.2% and 73.4% achieved these responses at Year 3 (mNRI). Among Week 16 PASI 100 responders, 76.3% also achieved Dermatology Life Quality Index (DLQI) 0\/1 at Week 16, and DLQI 0\/1 response increased with continuous BKZ treatment to 89.0% at Year 3 (mNRI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High levels of clinical response were maintained through to 3\u2005years of BKZ treatment in the vast majority of Week 16 responders. Long-term treatment with BKZ was efficacious, with important benefits for health-related quality of life, in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljad035","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T03:29:29Z","timestamp":1679887769000},"page":"749-759","source":"Crossref","is-referenced-by-count":43,"title":["Bimekizumab maintenance of response through 3\u2005years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yale University , New Haven, CT , USA"},{"name":"Central Connecticut Dermatology Research , Cromwell, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Teikyo University School of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Psoriasis Center, Department of Dermatology, University Medical Center Schleswig-Holstein , Campus Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[{"name":"The University of Melbourne, St Vincent\u2019s Hospital Melbourne , Fitzroy, Victoria , Australia"},{"name":"Probity Medical Research Inc., Skin Health Institute , Carlton, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"Langley","sequence":"additional","affiliation":[{"name":"Dalhousie University , Halifax, NS , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Wang","sequence":"additional","affiliation":[{"name":"UCB Pharma , Morrisville, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Vanvoorden","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balint","family":"Szilagyi","sequence":"additional","affiliation":[{"name":"UCB Pharma , Monheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Ciaravino","sequence":"additional","affiliation":[{"name":"UCB Pharma , Colombes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-5263","authenticated-orcid":false,"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Toulouse University and CHU , Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"2023112113513367900_ljad035-B1","doi-asserted-by":"crossref","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med"},{"key":"2023112113513367900_ljad035-B2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med"},{"key":"2023112113513367900_ljad035-B3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4103\/2229-5178.193908","article-title":"General measures and quality of life issues in psoriasis","volume":"7","author":"Sarkar","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"2023112113513367900_ljad035-B4","doi-asserted-by":"crossref","first-page":"585634","DOI":"10.3389\/fmed.2021.585634","article-title":"Epidemiological variations in the global burden of psoriasis, an analysis with trends from 1990 to 2017","volume":"8","author":"Peng","year":"2021","journal-title":"Front Med"},{"key":"2023112113513367900_ljad035-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: classical and emerging comorbidities","volume":"90","author":"Oliveira","year":"2015","journal-title":"An Bras Dermatol"},{"key":"2023112113513367900_ljad035-B6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/bjd.18361","article-title":"Complete skin clearance and PASI response rates in clinical practice-predictors, health related quality of life improvements and implications for treatment goals","volume":"182","author":"Norlin","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023112113513367900_ljad035-B7","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"2023112113513367900_ljad035-B8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Iskandar","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2023112113513367900_ljad035-B9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","article-title":"Drug survival of biologic treatments in psoriasis: a systematic review","volume":"29","author":"No","year":"2018","journal-title":"J Dermatol Treat"},{"key":"2023112113513367900_ljad035-B10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023112113513367900_ljad035-B11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2023112113513367900_ljad035-B12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023112113513367900_ljad035-B13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2023112113513367900_ljad035-B14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2023112113513367900_ljad035-B15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"2023112113513367900_ljad035-B16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2023112113513367900_ljad035-B17"},{"key":"2023112113513367900_ljad035-B18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2023112113513367900_ljad035-B19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/bjd\/ljac089","article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III\/IIIb trials","volume":"188","author":"Kokolakis","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023112113513367900_ljad035-B20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023112113513367900_ljad035-B21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5\u2005years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112113513367900_ljad035-B22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3\u2005years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2023112113513367900_ljad035-B23","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5\u2005years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112113513367900_ljad035-B24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3\u2005years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023112113513367900_ljad035-B25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/09546634.2016.1177158","article-title":"Review of maintenance of response to psoriasis treatments","volume":"27","author":"Bartos","year":"2016","journal-title":"J Dermatol Treat"},{"key":"2023112113513367900_ljad035-B26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"De Korte","year":"2004","journal-title":"J Invest Dermatol Symposium Proceedings"},{"key":"2023112113513367900_ljad035-B27","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"JAMA Dermatol"},{"key":"2023112113513367900_ljad035-B28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in patient-reported outcomes (Dermatology Life Quality Index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"20","author":"Armstrong","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2023112113513367900_ljad035-B29","author":"European Medicines Agency"},{"key":"2023112113513367900_ljad035-B30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13555-022-00693-2","article-title":"Biologic therapy for moderate to severe psoriasis. Real-world follow-up of patients who initiated biologic therapy at least 10\u2005years ago","volume":"12","author":"Elberd\u00edn","year":"2022","journal-title":"Dermatol Ther"},{"key":"2023112113513367900_ljad035-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-020-01395-6","article-title":"Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups","volume":"9","author":"Wade","year":"2020","journal-title":"System Rev"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad035\/49871934\/ljad035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/6\/749\/53664485\/ljad035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/6\/749\/53664485\/ljad035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T12:44:59Z","timestamp":1702125899000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/6\/749\/7086595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad035","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,27]]}}}